Surprised to see no reaction to this release from AVX. I thought...

Surprised to see no reaction to this release from AVX. I thought it was a pretty good update and gives a lot of information about what the company has done and how it sees itself advancing ATC to market. The release makes a good argument that AVX has a lot more going for it than 1.4c per share would suggest. This si a company with a drug effectively half way through phase 3 remember that is addressing a clear clinical need. I especially liked the mention of dealing with all the small parcels of shares out there that are too small to trade. Hopefully we hear more about that soon.